June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A vascular endothelial growth factor receptor inhibitor (VEGFRi) achieves topical efficacy in rat and monkey models of choroidal neovascularization (CNV)
Author Affiliations & Notes
  • Stephen H Poor
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
  • Yubin Qiu
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
  • Amber Woolfenden
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
  • Debby Long
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
  • Christopher M Adams
    Global Discovery Chemistry, Novartis Institute for Biomedical Research, Cambridge, MA
  • Jason Elliott
    Global Discovery Chemistry, Novartis Institute for Biomedical Research, Cambridge, MA
  • Vinayak Hosagrahara
    Neurosciences Innovative Medicines, AstraZeneca, Cambridge, MA
    Metabolism and Pharmacology, Novartis Institute of Biomedical research, Cambridge, MA
  • Jeremy M Sivak
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
    Glaucoma Research Chair, Toronto Western Research Institute, University of Toronto School of Medicine, Toronto, ON, Canada
  • Bruce D Jaffee
    Ophthalmology, Novartis Institute for Biomedical Research, Cambridge, MA
  • Footnotes
    Commercial Relationships Stephen Poor, Novartis Institute For Biomedical Research (E), Novartis Institute For Biomedical Research (E), Novartis Institute For Biomedical Research (E), Novartis Institute For Biomedical Research (E); Yubin Qiu, Novartis Institute For Biomedical Research (E); Amber Woolfenden, Novartis Institute For Biomedical Research (E); Debby Long, Novartis Institute For Biomedical Research (E); Christopher Adams, Novartis Institute For Biomedical Research (E), Novartis Institute For Biomedical Research (E); Jason Elliott, Novartis Institute For Biomedical Research (E); Vinayak Hosagrahara, Astrazeneca (E), Novartis Institute For Biomedical Research (E); Jeremy Sivak, Novartis Institute For Biomedical Research (E), Novartis Institute For Biomedical Research (E); Bruce Jaffee, Novartis Institute For Biomedical Research (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3380. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen H Poor, Yubin Qiu, Amber Woolfenden, Debby Long, Christopher M Adams, Jason Elliott, Vinayak Hosagrahara, Jeremy M Sivak, Bruce D Jaffee; A vascular endothelial growth factor receptor inhibitor (VEGFRi) achieves topical efficacy in rat and monkey models of choroidal neovascularization (CNV). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3380.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To explore the topical and oral pharmacokinetics (PK) and efficacy in rats and monkeys of CA-26-UY62 (UY62), a small molecule inhibitor of VEGF receptor-2

Methods: UY62 inhibits VEGFR-2 in a biochemical assay with an IC50 of 8.5 ± 3.3 nM. UY62 or vehicle was dosed topically (4 µL of 0.1 - 3% to both eyes) and q.d. orally (0.1 - 3 mg/kg/day) on day 0 - day 11 in a Brown Norway rat model of laser-induced CNV. Laser was applied on day 0 approximately I hour after the first dose, CNV area measured 12 days later by i.v. injection of a vascular label, flat mounts imaged and analysis of CNV area performed by morphometric analysis. There were 4 laser pulses per eye, 10 rats per group yielding 80 data points per group. In parallel, the ocular PK of oral (1 mg/kg/day q.d.) or topical (1% t.i.d.; 1.2 mg/kg/day) UY62 was determined in rats after the first dose and after a single dose on day 12. To demonstrate efficacy in a larger eye, cynomolgus monkeys were lasered (9 double spots to both eyes) and analyzed by fluorescein angiography (FA) at 2, 3, and 4 weeks. Lesions were graded 1 - 4.The number of Grade 4 lesions (lesions with bright hyperfluorescence and late leakage) were assessed. Monkeys were either dosed topically with 30 µL of 3% UY62 (~ 2 mg/kg/day) or placebo t.i.d. daily or with two IVT doses of 0.5 mg of Lucentis 2 weeks apart. Plasma PK was measured after 33 days of topical dosing.

Results: The oral ED50 and ED90 of UY62 in rats were 0.3 and 0.7 mg/kg respectively and the topical ED50 and ED90 of UY62 were 0.6 and 2.3% (based on 8 or 9 dose-response experiments for each dosing route). CNV fluorescein leakage studies in cynomolgus monkeys dosed with placebo showed 42, 37, and 33% grade 4 lesions at week 2, 3, and 4 respectively. Monkeys dosed topically with UY62 had grade 4 lesions reduced by 64 - 72%, compared to 94 - 100% with IVT Lucentis.<br /> Rat ocular and plasma PK were similar on day 1 and day 12 with no evidence of drug accumulation. However, the plasma AUC of UY62 on day 12 was 3 fold lower in topically dosed rats compared to orally dosed rats (12.7 vs 3.5 µM.h). In monkeys, the plasma AUC on day 37 with 3% t.i.d. formulation was lower than the plasma AUC in rats dosed with 1% t.i.d. (1.1 vs 3.5 µM.h).<br />

Conclusions: Topical UY62 is efficacious in both rat and monkey CNV models.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×